Core Viewpoint - Grabar Law Office is investigating claims on behalf of shareholders of Soleno Therapeutics regarding potential violations of federal securities laws related to misleading statements about the safety and commercial prospects of its drug candidate DCCR (VYKAT XR) [1][3]. Group 1: Investigation Details - The investigation focuses on whether Soleno and its executives made materially false and misleading statements about DCCR, particularly regarding its safety profile and clinical results [1][3]. - A federal securities fraud class action complaint has been filed, alleging that Soleno misrepresented DCCR's safety and efficacy, leading to significant stock price declines [3][7]. Group 2: Stock Performance and Impact - Following disclosures about the risks associated with DCCR, Soleno's stock price fell from a high of over $90 per share to below $45 per share, resulting in substantial losses for investors [3][7]. - The controversy surrounding DCCR has disrupted its commercial launch and negatively impacted physician adoption [7]. Group 3: Safety Concerns - Significant safety concerns regarding DCCR were allegedly downplayed or concealed, including evidence of excess fluid retention in clinical trial participants [7]. - Reports indicated that the integrity of Soleno's clinical trial data was questioned, and there were serious adverse safety events associated with the drug [7].

Core Viewpoint - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is recognized as a promising small-cap growth stock by hedge funds, despite a recent price target reduction by H.C. Wainwright analyst Raghuram Selvaraju from $120 to $100 while maintaining a Buy rating [1][6]. Financial Performance - For fiscal Q4 2025, Soleno reported quarterly revenue of $91.73 million, exceeding estimates by $3.18 million. The earnings per share (EPS) of $0.8 also surpassed consensus expectations by $0.09 [2]. - The revenue reflects less than nine months of commercial sales from the early adoption of VYKAT XR [2]. Market Outlook - The analyst projects a strong commercial outlook for Soleno, anticipating that VYKAT XR will capture 20% of the total market share for Prader-Willi syndrome [3]. - At the end of Q4 2025, there were 859 active patients on VYKAT XR treatment, an increase from 764 in Q3 [3]. Company Profile - Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare diseases, including Prader-Willi Syndrome [3].

Summary of Soleno Therapeutics FY Conference Call Company Overview - **Company**: Soleno Therapeutics (NasdaqCM:SLNO) - **Product**: VYKAT XR, the first approved drug for hyperphagia in Prader-Willi syndrome - **Recent Performance**: Generated approximately $190 million in revenue over the last three quarters [4][5] Key Insights on VYKAT XR Launch - **Market Potential**: The launch has confirmed a significant market presence with over 600 prescribers and coverage for more than 180 million lives [5][22] - **Reimbursement Success**: Strong reimbursement from over 45 Medicaid programs and Medicare being a top payer [5][22] - **Start Forms**: Anticipated to reach about 1,000 start forms over the next 9-12 months, with Q4 showing over 200 start forms [7][9] Patient Engagement and Treatment Dynamics - **Discontinuation Rates**: As of Q4, discontinuation rates due to adverse events were around 12%, with long-term expectations of 15%-20% [18][19] - **Efficacy Observations**: Early responses to treatment are noted, with maximal effects typically observed between 6-12 months [19][20] - **Patient Weight and Pricing**: Average patient weight is around 61 kg, with a wholesale acquisition cost (WAC) exceeding $500 [25] Coverage and Market Access - **Coverage Expansion**: Over 180 million lives covered, with expectations to stop reporting on covered lives post-Q1 [22][24] - **Prior Authorization Process**: Generally smooth for physicians, with reauthorizations typically ranging from 6 to 12 months [38] Future Opportunities - **New Indication**: Exploring VYKAT XR for Glycogen Storage Disease Type 1, with a significant unmet need and potential for a clinical trial to start later this year [58][61] - **European Market**: Estimated 9,500 patients in the EU, with a structured market landscape that may facilitate easier access compared to the U.S. [50][51] Strategic Considerations - **Life Cycle Management**: Ongoing discussions about life cycle extension strategies for VYKAT XR, with updates expected in the coming quarters [62] - **Community Engagement**: Strong relationships with advocacy organizations are fostering positive interactions and support for the product [65] Conclusion - **Market Opportunity**: The company emphasizes the substantial market potential for VYKAT XR, highlighting that even modest penetration could yield significant revenue [46][65]

Core Insights - The company achieved full-year profitability and positive cash flow within nine months of the VYKAT XR launch, driven by strong adoption in the PWS market [1] - Approximately 12.5% of the addressable U.S. market was captured by year-end, with 859 patients on active treatment and 1,250 total start forms received [1] - Durable growth is attributed to high prescriber engagement, with 630 unique prescribers and significant utilization across both pediatric and adult populations (ages 27-45) [1] - The company maintained a real-world safety profile consistent with clinical trials, reporting a 12% discontinuation rate due to adverse events against a total discontinuation rate of 15% [1] - Broad payer coverage has been secured for over 180 million lives, with efficient reauthorization processes noted due to recognized unmet needs in hyperphagia [1] - Strategic expansion beyond PWS is focused on Glycogen Storage Disease Type 1 (GSD 1), leveraging existing pediatric endocrinology call points and the drug's mechanism for insulin inhibition [1]

Financial Data and Key Metrics Changes - Total net revenue for Q4 2025 was $91.7 million, representing a sequential growth of nearly 40% from $66 million in Q3 2025 [18] - Full year 2025 total net revenue reached $190.4 million, with a positive net income of $20.9 million, marking a significant turnaround from a net loss of $175.9 million in 2024 [24] - Cash from operating activities for Q4 was $48.7 million, and the company ended the year with over $506 million in cash equivalents and marketable securities [5][18] Business Line Data and Key Metrics Changes - VYKAT XR, the company's primary product, achieved 1,250 patient start forms since its launch, capturing approximately 12.5% of the U.S. addressable market for Prader-Willi syndrome (PWS) [7][12] - Active treatment numbers increased from 764 at the end of Q3 to 859 by the end of Q4, indicating successful adoption into clinical practice [12] - The cumulative launch-to-date discontinuation rate related to adverse events was approximately 12% as of the end of Q4, with an expected long-term discontinuation rate of 15%-20% [8][14] Market Data and Key Metrics Changes - The company is targeting approximately 9,500 individuals living with PWS in the UK and EU4, with a concentrated market driven by centers of excellence [10] - Coverage for VYKAT XR has expanded to over 180 million lives across various channels, including commercial, Medicaid, and Medicare [16] Company Strategy and Development Direction - The company plans to expand beyond PWS, with Glycogen Storage Disease Type I (GSD I) identified as a potential new indication for VYKAT XR [26] - The strategy includes deepening experience and adoption among key opinion leaders (KOLs) and broadening the prescriber base in community settings [15][67] - The company is also considering commercialization options in the EU, with a focus on building its own team and capabilities [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining momentum for VYKAT XR, with strong leading indicators for growth [7] - The company anticipates a regulatory decision for DCCR in the EU by mid-2026, following the submission of responses to Day 120 questions [9][78] - Management highlighted the importance of real-world safety profiles and the positive feedback from caregivers and prescribers regarding VYKAT XR [8][14] Other Important Information - The company has a strong balance sheet, allowing for continued investment in commercialization and potential new indications [19] - Research and development expenses for Q4 were $9.6 million, significantly lower than the previous year, reflecting a strategic focus on commercialization [21][22] Q&A Session Summary Question: What is the expected cadence for the 1,000 patient start forms over the next 9-12 months? - Management indicated that the start forms will come in over the year rather than in a specific quarter [31][32] Question: What percentage of the market could be accessible for PWS in the U.S.? - Management suggested that a higher penetration than the typical 40%-50% could be expected due to the lack of existing treatments [37] Question: What are the refill rates and how might the average weight of new patients change over time? - Management reported high adherence rates and indicated that the average weight of new patients is expected to increase as more older patients are treated [41][42] Question: How does the company view exclusivity and patent prosecution for VYKAT XR? - Management confirmed ongoing efforts to extend exclusivity through additional patents, with some patents potentially extending into the late 2030s [71] Question: What are the expectations for the EU approval process? - Management expressed cautious optimism, noting that the nature of the key questions from the EMA focused on efficacy data [78]

Financial Data and Key Metrics Changes - Total net revenue for Q4 2025 was $91.7 million, representing a sequential growth of nearly 40% from $66 million in Q3 2025 [18] - Full-year 2025 total net revenue was $190.4 million, with a positive net income of $20.9 million and cash flow positive with $48.7 million generated from operating activities in Q4 [5][18] - The company ended the year with over $506 million in cash equivalents and marketable securities [5][18] Business Line Data and Key Metrics Changes - VYKAT XR received 1,250 patient start forms since its launch, capturing approximately 12.5% of the U.S. addressable market for Prader-Willi syndrome (PWS) [6][11] - Active treatment increased to 859 individuals by the end of Q4, up from 764 at the end of Q3 [11] - The cumulative launch-to-date discontinuation rate related to adverse events was approximately 12% as of the end of Q4, with an expected long-term discontinuation rate of 15%-20% [7][14] Market Data and Key Metrics Changes - The company anticipates capturing an additional approximately 1,000 patient start forms over the next nine to twelve months [6] - The U.K. and EU markets are estimated to have about 9,500 individuals living with PWS, with strong support from thought leaders for VYKAT XR [9] Company Strategy and Development Direction - The company plans to expand beyond PWS into other metabolic rare disease indications, starting with Glycogen Storage Disease Type I (GSD I) [26] - The strategy includes filing an IND for GSD I in the first half of 2026 and initiating a clinical program later that year [27] - The focus remains on successful commercialization of VYKAT XR in the U.S. and exploring opportunities in the EU and other geographies [64] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining momentum and capturing additional market share for VYKAT XR, highlighting strong engagement from prescribers and caregivers [6][12] - The management acknowledged the complexities of the PWS patient population and the importance of real-world safety profiles [7][14] - The company is optimistic about the upcoming regulatory decision in the EU and potential commercialization options [8][9] Other Important Information - The company has a strong balance sheet, ensuring sufficient capital for ongoing operations and potential new indications [19] - The CFO announced retirement plans, with a successor already identified to ensure a smooth transition [25] Q&A Session Summary Question: What is the expected cadence for the 1,000 patient start forms over the next nine to twelve months? - Management indicated that the start forms will come in over the year rather than in a specific quarter [31][32] Question: What percent of the market could be accessible in the U.S. for PWS? - Management suggested that higher penetration than 40%-50% is possible given the lack of other treatments [37] Question: What are the refill rates and how might the average weight of new patients change over time? - Management reported high adherence rates and expected that the average weight of new patients would likely increase over time [40][41] Question: How does the company view exclusivity and patent prosecution for VYKAT XR? - Management confirmed ongoing efforts to extend IP beyond current patents, with potential extensions into the late 2030s [68] Question: What are the expectations for the EU approval process? - Management noted that they are awaiting Day 180 questions from the EMA and are optimistic about the approval process despite challenges [75]

Financial Data and Key Metrics Changes - Total net revenue for Q4 2025 was $91.7 million, representing a sequential growth of nearly 40% from $66 million in Q3 2025. Full year revenue was $190.4 million, achieved in less than nine months of sales [4][19] - The company achieved profitability with a net income of $20.9 million for the full year 2025, compared to a net loss of $175.9 million for 2024 [24][19] - Cash flow from operating activities in Q4 was $48.7 million, and the company ended the year with over $506 million in cash equivalents and marketable securities [4][19] Business Line Data and Key Metrics Changes - VYKAT XR received 1,250 patient start forms since its launch, capturing approximately 12.5% of the U.S. addressable market for Prader-Willi syndrome (PWS) [5][11] - Active treatment increased to 859 individuals by the end of Q4, up from 764 at the end of Q3, indicating successful adoption into clinical practice [11][5] - The cumulative launch-to-date discontinuation rate for VYKAT XR related to adverse events was approximately 12% as of the end of Q4, with an expected long-term discontinuation rate of 15%-20% [6][5] Market Data and Key Metrics Changes - The company identified approximately 9,500 individuals living with PWS in the UK and EU4, with a concentrated market driven by centers of excellence [9] - The company secured broad coverage for VYKAT XR across all channels, covering over 180 million lives by the end of Q4 [15] Company Strategy and Development Direction - The company plans to expand beyond PWS, targeting additional metabolic rare disease indications, starting with Glycogen Storage Disease Type I (GSD I) [27] - The strategy includes leveraging the existing knowledge and skills from the VYKAT XR launch to address new indications with high unmet needs [29][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining momentum and capturing additional patient start forms over the next 9-12 months, indicating strong leading indicators [5][3] - The management acknowledged the complexity of PWS and the serious comorbidities of the patient population, emphasizing the importance of the real-world safety profile of VYKAT XR [6][5] Other Important Information - The company is preparing for potential approval of DCCR in the EU, with expectations for a decision in mid-2026 [8][7] - The CFO announced retirement at the end of March, with plans for a smooth transition to the new CFO [25][26] Q&A Session Summary Question: What is the expected cadence for the 1,000 patient start forms over the next 9-12 months? - Management indicated that the start forms will come in over the year rather than on a quarter-to-quarter basis [33][34] Question: What percentage of the market could be accessible in the U.S. for PWS? - Management suggested that a higher penetration than 40%-50% is possible given the lack of other treatments [39] Question: How are refill rates and average weight of new patients expected to change? - Management noted high adherence rates and expected that the average weight of new patients would likely increase over time due to more older patients being treated [42][44] Question: What is the company's strategy for exclusivity and patent prosecution for VYKAT XR? - Management confirmed ongoing efforts to extend exclusivity through additional IP filings and highlighted the potential for extending patents into the late 2030s [76] Question: What are the expectations for the EU approval process? - Management expressed cautious optimism, noting that they expect to receive Day 180 questions imminently and are prepared to address efficacy concerns raised by the EMA [82][81]

Core Viewpoint - Soleno Therapeutics (NASDAQ:SLNO) is identified as a promising biotechnology stock with significant upside potential, supported by positive analyst ratings and strong sales performance. Group 1: Analyst Ratings and Price Targets - Ram Selvaraju from H.C. Wainwright increased the price target for Soleno Therapeutics from $110 to $120, indicating an upside potential of nearly 211% and reaffirming a Buy rating [1] - Wells Fargo analyst Derek Archila maintained an Overweight rating and raised the price target from $106 to $114, suggesting a revised upside potential of 195% [3] Group 2: Financial Performance and Product Development - The fourth-quarter earnings for Vykat extended-release exceeded expectations, although new PSFs did not meet targets; management aims for approximately 250 new starts per quarter, excluding seasonal effects [4] - Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases, with its leading product being Diazoxide Choline Extended-Release tablets, VYKAT XR, which began commercialization in April 2025 following FDA approval [5]

Core Viewpoint - Soleno Therapeutics is currently not providing full-year guidance as it seeks to better understand its business dynamics, but management indicates that guidance may be offered in the future when more comfortable with the data [1] Group 1: Company Overview - Soleno Therapeutics is a commercial-stage company focused on rare diseases, specifically with an approved product for Prader-Willi syndrome (PWS), which is characterized by hyperphagia [3][18] - The company has been marketing its product for approximately three quarters [3] Group 2: Launch and Market Dynamics - The company expects to capture about 10% of the total addressable market (TAM), translating to approximately 1,000 start forms over a 9 to 12-month period, with variability from quarter to quarter [2][6] - The first-quarter report will be the last to disclose start-form metrics, after which the focus will shift to revenue and active patient reporting [2][6] Group 3: Reimbursement and Coverage - Reimbursement has exceeded expectations, with coverage through nearly 48 Medicaid programs and Medicare being a strong payer [5][14] - The prescriber base has grown to over 600, although many prescribers are new to PWS and require education on the drug [15] Group 4: Patient Conversion and Revenue - Start forms typically convert to active patients within 30 to 45 days, with a single-digit cancellation rate and overall discontinuation around 15% to 20% [6][8] - Revenue is primarily driven by active paid patients, adherence, wholesale acquisition cost (WAC), and gross-to-net dynamics [8] Group 5: International Regulatory Progress - The company is progressing with its European regulatory review, expecting Day 180 questions by the end of February for a patient pool of approximately 9,500 in the EU4 plus the UK [5][16] - Soleno is building its European team and is considering direct market engagement while also exploring partnerships [16] Group 6: Future Plans and Capital Deployment - Capital deployment priorities include supporting U.S. and international launches, pursuing additional indications for its product, and evaluating inorganic growth opportunities, though significant deals are not anticipated in the short term [17]

Summary of Soleno Therapeutics Conference Call Company Overview - **Company**: Soleno Therapeutics (NasdaqCM:SLNO) - **Industry**: Rare Disease Biopharmaceuticals - **Product**: First approved treatment for Prader-Willi syndrome (PWS), a genetic disorder characterized by hyperphagia, with no prior treatments available [5][38] Key Points and Arguments Market Position and Growth Expectations - Soleno currently holds approximately **10%** of the total addressable market (TAM) with a target of reaching another **10%** over the next **9-12 months**, equating to about **250 Start Forms** per quarter [7][12] - The company anticipates moving from Start Forms to traditional metrics of revenue and active patients after the first quarter of 2026 [10] - The expectation is that the holiday variability seen in the previous quarter will not recur, as there are no major holidays in the current quarter [8] Patient Flow and Revenue Generation - The process for Start Forms involves a **30-45 day** assessment period through their specialty pharmacy partner, Panther, with a small percentage of forms being canceled [14] - The discontinuation rate for patients is expected to stabilize between **15%-20%**, which is considered healthy for a rare disease context [15][24] - Active patient revenue is driven by a combination of paid and free patients, with adherence impacting overall revenue [17][18] Financial Guidance and Revenue Trends - Soleno is not providing full-year guidance for 2026 as the business is still maturing [11] - The company expects a **seasonal increase** in Gross to Net discounts in the first quarter due to resets in copay and potential changes in patient coverage [20][21] - The overall discontinuation rate as of the fourth quarter was approximately **15%**, with **12%** being adverse event-related [23] Clinical and Market Insights - Adverse events (AEs) reported in the real-world setting are consistent with those observed in clinical trials, primarily non-serious [26] - Most patients are titrating to their prescribed doses, with a few exceptions due to comorbidities [27][28] - The average wholesale acquisition cost (WAC) is currently in the **$500,000s**, with expectations of gradual increases over the next few years [31][32] Market Expansion and Reimbursement - Soleno has coverage for approximately **185 million lives**, with expectations for this number to increase as reimbursement policies improve [42] - The company is experiencing a favorable reimbursement environment, with no significant issues reported regarding prior authorizations [44] - There is a growing number of prescribers, with over **600** currently, which exceeds initial expectations [41] International Opportunities - The company is preparing for potential CHMP approval in Europe, with an estimated patient population of **9,500** in the EU and UK [47] - Soleno is considering launching the product independently in Europe while also exploring partnership opportunities [49] Capital Deployment Strategy - Soleno plans to focus on sustaining the success of its launch and exploring other indications, while also considering inorganic growth opportunities [50] Additional Important Insights - The company acknowledges the challenges of educating prescribers unfamiliar with PWS and the drug, which is crucial for improving treatment outcomes [45] - There is a noted social aspect influencing patient adherence and return to treatment, as positive patient experiences are shared within the community [34] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Soleno Therapeutics' current market position, growth expectations, and operational strategies in the rare disease sector.